NEW YORK – Oxford Nanopore Technologies has experienced quality problems with some commercial batches of Flongle flow cells, its most affordable sequencing chips that were released earlier this year, and is trying to scale up production to meet rising demand from users. While dealing with these issues, the company recently announced that it will start offering sequencing products for regulated applications, such as clinical assays and food testing, next year.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.